Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management

Anika Therapeutics, Inc.

Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).
Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.
Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.
Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.
Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.